The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis
Official Title: An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Etelcalcetide (AMG 416) in Paediatric Subjects Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Maintenance Haemodialysis
Study ID: NCT02833857
Brief Summary: This is a study to evaluate the safety and pharmacokinetics in pediatric patients with secondary hyperparathyroidism receiving a single dose of etelcalcetide at the end of hemodialysis.
Detailed Description:
Minimum Age: 2 Years
Eligible Ages: CHILD
Sex: ALL
Healthy Volunteers: No
Research Site, Los Angeles, California, United States
Research Site, Louisville, Kentucky, United States
Research Site, Kansas City, Missouri, United States
Research Site, Bruxelles, , Belgium
Research Site, Gent, , Belgium
Research Site, Leuven, , Belgium
Research Site, Hannover, , Germany
Research Site, Heidelberg, , Germany
Research Site, Köln, , Germany
Research Site, Marburg, , Germany
Research Site, Vilinus, , Lithuania
Research Site, Krakow, , Poland
Research Site, London, , United Kingdom
Name: MD
Affiliation: Amgen
Role: STUDY_DIRECTOR